0
$0.00
Retatrutide

BATCH

PURITY

99% HPLC

  • CAS #:
  • 2381089-83-2
  • Formula:
  • C₂₂₁H₃₄₂N₄₆O₆₈
  • M.W.:
  • 4731.33

Retatrutide

Appetite ReshapingVisceral Fat ReductionWeight Loss

From $140.00

Volume Pricing Guide

QUANTITY PRICE PER
1 $140.00
2 - 4 $126.00
5 - 9 $119.00
10 - 14 $112.00
15 - 19 $105.00
20 + $98.00
Only the lyophilized product is provided. All supplies sold separately. For research use only.

Summary

Retatrutide (LY3437943) is a groundbreaking investigational peptide therapy that activates three key metabolic hormone receptors—GLP-1, GIP, and glucagon—delivering unprecedented weight loss outcomes. In phase 2 trials, participants achieved up to a 24.2% reduction in body weight over 48 weeks, surpassing results from existing GLP-1 or dual agonist therapies . This triple-agonist approach not only enhances satiety and insulin sensitivity but also increases energy expenditure, offering a comprehensive strategy for metabolic health restoration.

Description & Pharmacodynamics

Retatrutide’s unique mechanism of action involves simultaneous activation of:

  • GLP-1 Receptors: Enhances insulin secretion, delays gastric emptying, and promotes satiety.
  • GIP Receptors: Improves insulin sensitivity and supports lipid metabolism.
  • Glucagon Receptors: Increases energy expenditure and promotes fat oxidation.

This synergistic activation leads to:

  • Significant Weight Reduction: Up to 24.2% body weight loss observed in clinical trials .
  • Improved Glycemic Control: Enhanced insulin sensitivity and glucose regulation.

Cardiometabolic Benefits: Potential improvements in blood pressure and lipid profiles.

Research Insights

Superior Weight Loss Outcomes
In a 48-week phase 2 study, adults with obesity treated with retatrutide experienced mean weight reductions of 22.8% (8 mg dose) and 24.2% (12 mg dose), outperforming other weight loss medications .

Enhanced Metabolic Health
Beyond weight loss, retatrutide has demonstrated potential in reducing liver fat content, indicating benefits for conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) .

Tolerability and Safety
Common side effects were primarily gastrointestinal and occurred mainly during dose escalation phases. These effects were generally mild to moderate and transient .

Structure

Retatrutide Sequence:
YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³
Note: Superscript numbers indicate specific chemical modifications enhancing stability and receptor activity.

Molecular Formula: Variable
Molecular Weight: Variable
PubChem CID: Not yet assigned

Citations for Retatrutide

  1. Jastreboff, A. M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. The New England Journal of Medicine. 
  2. Nature Medicine. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction. 
  3. American Diabetes Association. (2023). Highlights Novel Agent Retatrutide Results: Substantial Weight Reduction.

**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.

Researched Pairings

AOD-9604

Fat Burner

$88.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Cagrilintide

FAT LOSS

$220.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Semaglutide

"OZEMPIC" PEPTIDE

From $95.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Semaglutide / Cagrilintide

2ND GENERATION "OZEMPIC"

$220.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Tesamorelin

CORE STRENGTH

$145.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Tirzepatide

"MOUNJARO" PEPTIDE

From $250.00

View
Buy This product has multiple variants. The options may be chosen on the product page